Lenalidomide also downregulates key genes involved in the MM angiogenesis (VEGF and FGF-2) and cell migration (CCL2 and CXCL12), and other genes governing the angiogenic process (BNIP3, IER3, SEPW1, COL4A1, CRYAB, and Notch1). This evidence concerns the gene VEGFA and Miyoshi myopathy.